The prosecution of global businesses under the Foreign Corrupt Practices Act (FCPA) is on the rise, with Pharmaceutical and Life Sciences companies at the top of the DOJ's list for investigations. Recently, a Pharma and Life Sciences company agreed to pay $70 million in FCPA penalties.
Date Recorded: 06/29/2011 Sponsored by: Aravo
Speaker: William P. Barry, Partner, Richards Kibbe & Orbe LLP
View OnDemand Webinar
All PharmaVOICE Webinars
